SCHEMBL10174975

SCHEMBL10174975

CCOc1cc(NC(=O)NCC(F)(F)F)cc(B2OC(C)(C)C(C)(C)O2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.47
LMNA P02545 3/20 0.47
KMT2A Q03164 3/20 0.47
PAX8 Q06710 2/20 0.47
KDR P35968 3/20 0.40
FGFR3 P22607 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.38
MAPT P10636 3/20 0.37
HTT P42858 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
S1PR2 O95136 1/20 0.37
S1PR4 O95977 1/20 0.37
GAA P10253 1/20 0.37
XBP1 P17861 1/20 0.37
S1PR3 Q99500 1/20 0.37
S1PR5 Q9H228 1/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 1/20 0.37
HIF1A Q16665 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11925795 0.89 L3MBTL1 (0.39) LMNAKMT2AKDRFGFR3L3MBTL1
SCHEMBL600503 0.86 FGFR4 (0.43) MEN1LMNAKMT2APAX8KDR
SCHEMBL11925794 0.83 L3MBTL1 (0.41) KDRFGFR3L3MBTL1PDGFRBCXCR2
SCHEMBL15693723 0.81 L3MBTL1 (0.39) KDRFGFR3L3MBTL1SMN1; SMN2DGAT1
SCHEMBL73204 0.79 L3MBTL1 (0.50) KDRFGFR3L3MBTL1PDGFRB
SCHEMBL10225526 0.79 L3MBTL1 (0.38) KDRFGFR3L3MBTL1SMN1; SMN2PDGFRB
SCHEMBL15567289 0.78 L3MBTL1 (0.48) MEN1KMT2AKDRL3MBTL1DGAT1
SCHEMBL3319893 0.78 L3MBTL1 (0.52) KDRFGFR3L3MBTL1DGAT1PDGFRB
SCHEMBL10174980 0.77 MEN1 (0.54) MEN1LMNAKMT2APAX8KDR
SCHEMBL600754 0.75 PIK3CA (0.39) KDRHIF1APDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722687-B2 Imidazo [1,2-A]pyridine derivatives as FGFR kinase inhibitors for use in therapy ASTEX THERAPEUTICS LTD (GB) 2014-05-13 US disclosed
US-8722687-B2 Imidazo [1,2-A]pyridine derivatives as FGFR kinase inhibitors for use in therapy ASTEX THERAPEUTICS LTD (GB) 2014-05-13 US disclosed
US-20120041000-A1 IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY ASTEX THERAPEUTICS LIMITED (GB) 2012-02-16 US disclosed
US-20120041000-A1 IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY ASTEX THERAPEUTICS LIMITED (GB) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041000-A1 IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY FGFR1, FGFR3, FGFR2 MEN1 2623/4885LMNA 4125/4885KMT2A 1043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.